Improving Cancer Treatment using Nanomedicines: CriPec® and CPC634

3/9/2020 13:50 - 14:25

  • Broadly applicable CriPec® platform enables rational design of nanotherapeutics for oncology and other disease areas
  • CPC634: clinical translation from bench to bedside
  • Confirmation of CriPec® tumour uptake in patients via PET/CT visualisation
  • Outlook nanomedicine exploitation: experimental evidence of being broadly applicable with various drug modalities
  • Proprietary CliCr® as a superior click chemistry reagent provides fast access to desired stable conjugated products with high conversion rates

Rachel Hu, Senior Formulation Scientist, Cristal Therapeutics

Back to programme